-
Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation
Michael G Kenward
Clinical Trail Methodology: Clinical Investigation
-
Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation
Michael G Kenward
Clinical Trail Methodology: Clinical Investigation
-
Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation
Michael G Kenward
Clinical Trail Methodology: Clinical Investigation
-
Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation
Michael G Kenward
Clinical Trail Methodology: Clinical Investigation
-
Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation
Michael G Kenward
Clinical Trail Methodology: Clinical Investigation
-
Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation
Michael G Kenward
Clinical Trail Methodology: Clinical Investigation
-
Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation
Michael G Kenward
Clinical Trail Methodology: Clinical Investigation
-
Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation
Michael G Kenward
Clinical Trail Methodology: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Clinical trial outsourcing
Shurjeel Choudhri
Expert Review: Clinical Investigation
-
Clinical trial outsourcing
Shurjeel Choudhri
Expert Review: Clinical Investigation
-
Clinical trial outsourcing
Shurjeel Choudhri
Expert Review: Clinical Investigation
-
Clinical trial outsourcing
Shurjeel Choudhri
Expert Review: Clinical Investigation
-
Clinical trial outsourcing
Shurjeel Choudhri
Expert Review: Clinical Investigation
-
Clinical trial outsourcing
Shurjeel Choudhri
Expert Review: Clinical Investigation
-
Clinical trial outsourcing
Shurjeel Choudhri
Expert Review: Clinical Investigation
-
Clinical trial outsourcing
Shurjeel Choudhri
Expert Review: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation